miRNA Detargeting Cassette for Tissue-Specific RNA Interference
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNAi-based gene therapy methods lack the ability to achieve tissue-specific expression of microRNAs, leading to unintended high levels of gene expression in non-target tissues, particularly in the liver when using liver-specific promoters.
Innovation Solution
A system is developed that incorporates tissue-specific promoters and miRNA mature guide strands with detargeting sequences, such as miR-122 and miR-208 binding sites, to inhibit gene expression in specific tissues like the liver and heart, using recombinant adeno-associated virus (rAAV) vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ubiquitously active promoters (e.g., U6) are used to drive miRNA expression, then high expression levels are achieved across all tissues, but tissue-specificity is lost leading to off-target effects
Solution Approach 1:
The patent introduces tissue-specificity into the miRNA expression system by incorporating detargeting sequences that are specific to certain tissues (e.g., liver-specific miR-122 binding sites). This creates local quality differences where the same miRNA expression cassette behaves differently in different tissues - highly active in non-target tissues but suppressed in tissues containing the detargeting sequences, thereby eliminating off-target effects while maintaining therapeutic efficacy in the desired tissue
Solution Approach 2:
Instead of directly targeting miRNA expression to specific tissues through tissue-specific promoters, the patent inverts the approach by using ubiquitous promoters combined with detargeting sequences. The detargeting sequences work by being recognized by tissue-specific miRNAs to suppress expression in those particular tissues, effectively achieving tissue-specificity through suppression rather than activation
2Reliability
If detargeting sequences are inserted into the miRNA mature guide strand, then tissue-specific inhibition is achieved, but device complexity increases
Solution Approach 1:
The patent incorporates multiple copies of detargeting sequences (e.g., two or more miR-122 binding sites) within the miRNA mature guide strand to ensure sufficient suppression strength in target tissues. This partial or excessive action guarantees that even with the added complexity of multiple sequences, the tissue-specific inhibition is robust and reliable, achieving the desired tissue-specificity without compromising therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces gene expression in non-target tissues by 50-70-fold, ensuring precise tissue-specific inhibition or replacement of miRNA, thereby enhancing the efficacy of RNAi-based therapies.
Implementation Method 1
RNA interference (RNAi) is a mechanism of gene regulation in eukaryotic cells that has been considered for the treatment of various diseases. RNAi refers to post-transcriptional control of gene expression mediated by microRNAs (miRNAs). The interaction between the miRNAs and mRNAs directs cellular gene silencing machinery to degrade target mRNA and/or prevent the translation of the mRNAs.
Data Source
AI summary
The present disclosure relates to a tissue-specific promoter system for expressing microRNA (miRNA) for RNA interference-based methods of gene therapy. In these systems, the miRNA will inhibit gene expression or replace natural miRNA expression using microRNA.